Caxton Associates LLP Has $342,000 Stake in Boston Scientific Corporation $BSX

Caxton Associates LLP lowered its position in shares of Boston Scientific Corporation (NYSE:BSX) by 67.5% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 5,445 shares of the medical equipment provider’s stock after selling 11,307 shares during the period. Caxton Associates LLP’s holdings in Boston Scientific were worth $342,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of BSX. Outfitters Financial LLC grew its holdings in shares of Boston Scientific by 0.5% during the fourth quarter. Outfitters Financial LLC now owns 24,027 shares of the medical equipment provider’s stock worth $2,291,000 after purchasing an additional 110 shares during the last quarter. Natural Investments LLC boosted its position in Boston Scientific by 2.9% during the 4th quarter. Natural Investments LLC now owns 4,036 shares of the medical equipment provider’s stock worth $384,000 after buying an additional 112 shares during the period. Patton Fund Management Inc. grew its holdings in Boston Scientific by 5.5% during the 4th quarter. Patton Fund Management Inc. now owns 2,279 shares of the medical equipment provider’s stock worth $217,000 after acquiring an additional 118 shares during the last quarter. Bridgewater Advisors Inc. increased its position in Boston Scientific by 1.2% in the 4th quarter. Bridgewater Advisors Inc. now owns 10,051 shares of the medical equipment provider’s stock valued at $921,000 after acquiring an additional 123 shares during the period. Finally, Earned Wealth Advisors LLC raised its stake in shares of Boston Scientific by 5.2% during the fourth quarter. Earned Wealth Advisors LLC now owns 2,647 shares of the medical equipment provider’s stock valued at $252,000 after acquiring an additional 131 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Leerink Partners cut their price target on shares of Boston Scientific from $87.00 to $74.00 and set an “outperform” rating on the stock in a report on Thursday, May 28th. Canaccord Genuity Group decreased their price objective on Boston Scientific from $71.00 to $70.00 and set a “buy” rating for the company in a report on Monday, June 1st. Bank of America lowered their target price on Boston Scientific from $105.00 to $68.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Daiwa Securities Group downgraded Boston Scientific from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. Finally, Truist Financial reduced their price target on Boston Scientific from $64.00 to $62.00 and set a “buy” rating on the stock in a research report on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $78.40.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific’s board approved a global restructuring plan expected to generate approximately $500 million in annual cost savings by 2029. Management says the initiative is intended to improve efficiency and support future growth, which may strengthen long-term profitability. Reuters restructuring report
• Positive Sentiment: Investors are positioning ahead of Wednesday’s second-quarter results. Analysts reportedly expect revenue growth of about 5.9%, creating a potential catalyst if Boston Scientific delivers stronger-than-expected sales or guidance. Q2 earnings preview
• Positive Sentiment: The company’s FARAFLEX trial is advancing its pulsed-field ablation program for atrial fibrillation, potentially supporting Boston Scientific’s position in the growing cardiac-rhythm-treatment market. FARAFLEX trial update
• Neutral Sentiment: UBS maintained a Buy rating despite lowering its price target to $74 from $95. Oppenheimer likewise cut its target to $85 but retained an Outperform rating, indicating continued confidence but more cautious valuation assumptions. UBS price-target update
• Negative Sentiment: The restructuring will involve job cuts through 2029 and approximately $700 million in restructuring costs, creating near-term execution, employee-disruption and cash-flow concerns even though the plan promises future savings. Restructuring and job cuts report

Boston Scientific Stock Up 1.2%

Shares of NYSE BSX opened at $46.04 on Wednesday. The company’s 50 day moving average price is $46.78 and its 200-day moving average price is $63.10. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. Boston Scientific Corporation has a 52-week low of $42.20 and a 52-week high of $109.50. The company has a market capitalization of $68.44 billion, a P/E ratio of 19.27, a price-to-earnings-growth ratio of 0.87 and a beta of 0.58.

Boston Scientific announced that its board has approved a stock repurchase program on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares buyback programs are typically a sign that the company’s board of directors believes its stock is undervalued.

Insider Buying and Selling

In other news, Director Cheryl Pegus purchased 1,770 shares of the business’s stock in a transaction on Wednesday, May 20th. The shares were acquired at an average price of $56.49 per share, with a total value of $99,987.30. Following the completion of the transaction, the director owned 1,770 shares of the company’s stock, valued at $99,987.30. The trade was a ? increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Edward J. Ludwig acquired 3,580 shares of the stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average cost of $56.68 per share, with a total value of $202,914.40. Following the completion of the transaction, the director owned 25,359 shares in the company, valued at approximately $1,437,348.12. This represents a 16.44% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought 9,800 shares of company stock valued at $554,012 over the last quarter. Insiders own 0.34% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.